ClinVar Miner

Submissions for variant NM_015192.4(PLCB1):c.639A>C (p.Arg213Ser)

gnomAD frequency: 0.00014  dbSNP: rs140899287
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001079973 SCV000561037 benign Developmental and epileptic encephalopathy, 12 2024-01-12 criteria provided, single submitter clinical testing
Ambry Genetics RCV002313226 SCV000847472 likely benign Inborn genetic diseases 2018-04-19 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
GeneDx RCV000828396 SCV000970082 likely benign not provided 2023-11-03 criteria provided, single submitter clinical testing See Variant Classification Assertion Criteria.
PreventionGenetics, part of Exact Sciences RCV003972791 SCV004789021 benign PLCB1-related condition 2023-10-18 criteria provided, single submitter clinical testing This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.